Breakout Point
12.9K posts
Breakout Point
@BreakoutPoint
We uncover Big Shorts & track Meme Stocks. Impressum: https://t.co/dfZeLDCtvL Posts are not investment advice.
Today, we closed our latest funding round with $122 billion in committed capital at an $852B post-money valuation. The fastest way to expand AI’s benefits is to put useful intelligence in people’s hands early and let access compound globally. This funding gives us resources to lead at scale. openai.com/index/accelera…
I asked Europe's main producer of tanks and artillery what he thinks about the cheap drones wrecking all those tanks and artillery pieces in Ukraine. "This is not innovation," he said of the Ukrainian weapons. "This is how to play with Legos." An exclusive interview with Armin Papperger in my profile of his company, @RheinmetallAG, whose stock price has grown 15-fold since the Russian invasion, as the Europeans buy up all the tanks and artillery he can produce. Out today @TheAtlantic. Gift link below.
$WATT Update: In under 90 days, the float more than doubled. 139% more shares outstanding. After our report the stock is down -25%. Oblivious shareholders just found out their shares are worth at most half of what they paid. Tigers don't change their stripes. See our full report ⬇️ fugaziresearch.com/p/watt-a-decad…
$SIVE (SIVE.ST) Aggregate short interest at 4.01% (up from 3.23% yesterday) Qube further boosted their short yesterday (latest at 2.06%) Get VIP shorts breakoutpoint.com
1/5 Citron is short $VCX . $VCX is trading at $400+. Its assets are worth $19. SIMPLE MATH. The sponsor was fined by the SEC for paying 200+ influencers to promote their products without disclosure — willfully, for five years. They registered the domain GetVCX.com. Not VCXinfo. Not learnaboutVCX. Get. The domain name itself is the pitch. Their own prospectus discloses "Other Expenses – Marketing: 0.42%" charged to investors — roughly $3 million a year on a publicly traded security. Who is getting that money? . Full thread below. 🧵
Well this post aged well on $VCX. Just 1 hour later?
NEW: We are short ADMA Biologics $ADMA. We believe the ASCENIV growth story is in reality a story of channel stuffing and an undisclosed related party distributor. Real revenues declined 3% in 2025 vs. 20% reported growth. It's already over. Full report available on our website.
NEW: We are short ADMA Biologics $ADMA. We believe the ASCENIV growth story is in reality a story of channel stuffing and an undisclosed related party distributor. Real revenues declined 3% in 2025 vs. 20% reported growth. It's already over. Full report available on our website.